TABLE 2.

Summary of main characteristics of the selected clinical trials.

Author/Study Acronim	Study design	Patient Eligibility	Dose	Number of Patients	Duration	Primary Endpoints	Statistical Analysis	Quality of Evidence (GRADE)
Paller (Paller et al., 2008)	Multicentre, double-blind	PASI≥12	⁃Etanercept 0.8 mg/kg (max 50 mg)	106	12 weeks	PASI 75	Intention to treat	⊕⊕ high
		PGA≥3	⁃Placebo	105
		BSA≥10%
Papp (Papp et al., 2017)	Multicentre, double-blind, multiperiod, phase 3 trial	PASI≥20 or ≥10 and at least one of active psoriatic arthritis unresponsive to non-steroidal anti-inflammatory drugs	⁃Adalimumab 0.8 mg/kg (max 40 mg)	38	16 weeks	PASI 75	Intention to treat	⊕⊕ high
		PGA≥4	⁃Adalimumab 0.4 mg/kg (max 20 mg)	39		PGA 0/1
		BSA>20% or ≥10% with very thick lesions	⁃Methotrexate 0.1–0.4 mg/kg (max 25 mg per week total dose)	37
		CDLQI≥10 or clinically relevant facial, genital, or hand or foot involvement
Landells/CADMUS (Landells et al., 2015)	Multicentre, double-blind, phase 3 trial	PASI≥12	⁃Ustekinumab Standard Dose 0.75 mg/kg	36	12 weeks	PGA 0/1	Non responder imputation	⊕⊕ high
		PGA≥3	⁃Ustekinumab Half-Standard Dose 0.375 mg/kg	37
		BSA≥10%	⁃Placebo	37
Bodemer (Bodemer et al., 2021)	Multicentre, double-blind, placebo- and active controlled	PASI≥20	⁃Secukinumab low dose (LD) 150 mg	40	12 weeks	PASI 75	Non responder imputation	⊕⊕ high
		IGA≥4	⁃Secukinumab high dose (HD) 300 mg	40		IGA 0/1
		BSA≥10	⁃Etanercept	41
			⁃Placebo	41
Paller/IXORA Ped (Paller et al., 2020)	Multicentre, double-blind, phase 3 trial	PASI ≥20 sPGA ≥4	⁃Ixekizumab1	115	12 weeks	PASI 75 sPGA 0/1	Non responder imputation	⊕⊕ high
			⁃Placebo	56

According to body weight, dosing was as follows: subjects >50 kg received a starting dose of 160 mg, then 80 mg every 4 weeks (Q4W) thereafter; subjects 25–50 kg received a starting dose of 80 mg, then 40 mg Q4W thereafter; subjects <25 kg received a starting dose of 40 mg, then 20 mg Q4W thereafter).